

Post Grant Review No. PGR 2016-00008
Patent No. 9,173,942
Petitioner's Request for Partial Rehearing Regarding
Decision Denying Institution of Post Grant Review
Attorney Docket No. REDDY 7.2R-022

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES, LTD. and
DR. REDDY'S LABORATORIES, INC.,
Petitioners

v.

HELSINN HEALTHCARE S.A. and ROCHE PALO ALTO LLC,
Patent Owners.

U.S. Patent No. 9,173,942 to Giorgio Calderari *et al.*
Issue Date: November 3, 2015

Title: LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON

Post Grant Review No. PGR2016-00008

**PETITIONERS' REQUEST FOR PARTIAL REHEARING REGARDING
DECISION DENYING INSTITUTION OF POST GRANT REVIEW**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

	Page
TABLE OF AUTHORITIES	ii
I. INTRODUCTION AND SUMMARY OF ARGUMENT.....	1
II. ARGUMENT.....	3
A. The Board Improperly Limited <i>Cooper Cameron</i> To The Facts Of <i>Gentry Gallery</i>	3
B. The “Entirety Of The Specification” Makes Clear That Stability Is An Essential Element Of The Invention	6
1. The Portions Of The Specification Quoted By The Board, And The Portions The Board Overlooked, Make This Clear	6
2. A Person Of Ordinary Skill Would Not Understand The ’942 Inventors To Have Invented Unstable Formulations	7
C. The Patent Owner’s Arguments Also Support Petitioner’s Position	9
D. There Must Be Written Description Support For The Full Scope Of The Claims	9
E. Reciting Selected Ingredients Is Not Sufficient To Justify The Failure To Require Stability In The Claims	10
F. Recent Precedent Further Supports Institution Of Post Grant Review	11
III. CONCLUSION.....	12

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>Abbvie Deutschland GmbH & Co. v. Janssen Biotech Inc.</i> , 759 F.3d 1285 (Fed. Cir. 2014)	9
<i>Arnold P'ship v. Dudas</i> , 362 F.3d 1338 (Fed. Cir. 2004)	3
<i>Bamberg v. Dalvey</i> , 815 F.3d 793 (Fed. Cir. 2016)	11, 12
<i>Cooper Cameron Corp. v. Kvaerner Oilfield Prods., Inc.</i> , 291 F.3d 1317 (Fed. Cir. 2002)	3, 4, 5
<i>Gentry Gallery, Inc. v. Berkline Corp.</i> , 134 F.3d 1473 (Fed. Cir. 1998)	3, 4
<i>ICU Med., Inc. v. Alaris Med. Sys., Inc.</i> , 558 F.3d 1368 (Fed. Cir. 2009)	7
<i>PIN/NIP, Inc. v. Platte Chem. Co.</i> , 304 F.3d 1235 (Fed. Cir. 2002) (Petition 27-28).....	4
<i>Star Fruits S.N.C. v. United States</i> , 393 F.3d 1277 (Fed. Cir. 2005)	3
<i>Univ. of Rochester v. G.D. Searle & Co.</i> , 358 F.3d 916 (Fed. Cir. 2004)	9, 10
STATUTES, RULES & OTHER AUTHORITIES	
35 U.S.C. § 112(a)	1, 5, 13
37 C.F.R. § 42.71(c).....	1, 2
37 C.F.R. § 42.71(d)	1
37 C.F.R. § 42.71(d)(2).....	1

I. INTRODUCTION AND SUMMARY OF ARGUMENT

Pursuant to 37 C.F.R. § 42.71(c) and (d), Petitioner respectfully requests rehearing with regard to only Part C of the Board's August 17, 2016 Decision denying institution of post grant review ("Decision"), appearing at pages 10-13 thereof and addressing written description under 35 U.S.C. § 112(a). This request is timely filed within 30 days of the entry of the Board's Decision, as set forth in 37 C.F.R. § 42.71(d)(2).

Petitioner respectfully submits that the Board misapplied the law, as set forth at pages 24-30 of the Petition, requiring that the "entirety of the specification" be used to determine whether, to one skilled in the art, the invention described in the specification is of a much narrower scope than that later claimed in U.S. Patent No. 9,173,942 ("the '942 Patent").

In fact, the Board is believed to have overlooked the vast majority of the specification of the '942 Patent which demonstrates that the "entirety of the specification" is directed to palonosetron formulations having enhanced stability, as set forth at pages 10-14 of the Petition, whereas the claims omit any requirement of stability. Even the portions of the specification the Board cited at pages 3-5 of the Decision support Petitioner's position. Collectively, *all* of these portions

demonstrate the narrow invention of stable palonosetron formulations described in the specification as a whole, which is in stark contrast to the claims.

The Board also misapprehended the Patent Owner's argument discussed at page 10 of the Decision, which actually confirms Petitioner's contention that increased stability was and is the central purpose of the '942 Patent as a whole.

Still further, the Board is believed to have overlooked the Declaration of Dr. Christopher A. Fausel (Exh. 1038 (cited in the Petition at 25, 27, 30)), which provided the only direct evidence in this record as to how a person of ordinary skill would have viewed the entirety of the specification: the specification limits the proper scope of the claims to *stable* formulations.

Petitioner also respectfully submits that the Board overlooked the Patent Owner's numerous prior patents having the same specification as the '942 Patent, discussed at pages 16-18 of the Petition. Those prior patents contradict the Board's conclusion (Decision 12) that recitation of certain selected ingredients and concentrations in the '942 claims make it unnecessary for the '942 claims to recite stability.

Under 37 C.F.R. § 42.71(c), "[w]hen rehearing a decision on petition, a panel will review the decision for an abuse of discretion." An abuse of discretion

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.